Citius Pharmaceuticals (CTXR) Competitors $1.53 -0.07 (-4.08%) Closing price 04:00 PM EasternExtended Trading$1.59 +0.06 (+3.92%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTXR vs. INCR, PMVP, VTGN, GNTA, RPTX, IRD, ANEB, IKNA, KLTO, and CNTXShould you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include InterCure (INCR), PMV Pharmaceuticals (PMVP), VistaGen Therapeutics (VTGN), Genenta Science (GNTA), Repare Therapeutics (RPTX), Opus Genetics (IRD), Anebulo Pharmaceuticals (ANEB), Ikena Oncology (IKNA), Klotho Neurosciences (KLTO), and Context Therapeutics (CNTX). These companies are all part of the "pharmaceutical products" industry. Citius Pharmaceuticals vs. Its Competitors InterCure PMV Pharmaceuticals VistaGen Therapeutics Genenta Science Repare Therapeutics Opus Genetics Anebulo Pharmaceuticals Ikena Oncology Klotho Neurosciences Context Therapeutics Citius Pharmaceuticals (NASDAQ:CTXR) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings. Is CTXR or INCR more profitable? InterCure's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Citius PharmaceuticalsN/A -58.63% -37.67% InterCure N/A N/A N/A Do analysts rate CTXR or INCR? Citius Pharmaceuticals presently has a consensus price target of $53.00, indicating a potential upside of 3,364.05%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Citius Pharmaceuticals is more favorable than InterCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50InterCure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to CTXR or INCR? In the previous week, Citius Pharmaceuticals had 2 more articles in the media than InterCure. MarketBeat recorded 4 mentions for Citius Pharmaceuticals and 2 mentions for InterCure. InterCure's average media sentiment score of 1.07 beat Citius Pharmaceuticals' score of 0.31 indicating that InterCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InterCure 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, CTXR or INCR? Citius Pharmaceuticals has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Which has better earnings & valuation, CTXR or INCR? InterCure has higher revenue and earnings than Citius Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius PharmaceuticalsN/AN/A-$39.14MN/AN/AInterCure$64.55MN/A-$18.32MN/AN/A Do institutionals & insiders believe in CTXR or INCR? 16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 10.7% of Citius Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of InterCure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryCitius Pharmaceuticals beats InterCure on 7 of the 12 factors compared between the two stocks. Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTXR vs. The Competition Export to ExcelMetricCitius PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.96M$2.73B$5.52B$9.41BDividend YieldN/A1.79%3.80%4.04%P/E RatioN/A8.9428.0419.84Price / SalesN/A697.47429.5399.59Price / CashN/A161.2635.8457.94Price / Book0.155.008.125.65Net Income-$39.14M$30.99M$3.25B$258.00M7 Day Performance-1.92%1.69%0.97%2.09%1 Month Performance67.65%9.20%7.36%11.13%1 Year Performance-92.60%-1.25%31.31%18.40% Citius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTXRCitius Pharmaceuticals3.0708 of 5 stars$1.53-4.1%$53.00+3,364.1%-92.2%$16.96MN/A0.0020INCRInterCure0.5776 of 5 stars$1.55flatN/A-37.8%$70.63M$238.85M0.00350PMVPPMV Pharmaceuticals3.1933 of 5 stars$1.35+7.1%$5.50+307.4%-17.4%$70.13MN/A-1.1450Gap UpHigh Trading VolumeVTGNVistaGen Therapeutics0.665 of 5 stars$2.38flatN/A-34.0%$69.40M$490K-1.4340Positive NewsGNTAGenenta Science2.4989 of 5 stars$3.78-4.5%$25.00+561.4%+4.4%$69.14MN/A0.007Gap UpRPTXRepare Therapeutics2.801 of 5 stars$1.57+4.7%$4.50+186.6%-58.7%$67.34M$53.48M-0.52180News CoverageGap DownIRDOpus Genetics1.6936 of 5 stars$1.11-1.8%$7.33+560.7%N/A$66.22M$10.99M-0.5314ANEBAnebulo Pharmaceuticals2.4476 of 5 stars$1.61-3.0%$5.50+241.6%-27.8%$66.15MN/A-6.194News CoveragePositive NewsIKNAIkena Oncology2.8041 of 5 stars$1.37-0.7%$3.00+119.0%-25.9%$66.11MN/A-1.5970High Trading VolumeKLTOKlotho NeurosciencesN/A$1.25-3.8%N/AN/A$65.88MN/A-3.47N/ACNTXContext Therapeutics3.3595 of 5 stars$0.73+9.3%$5.50+651.2%-55.3%$65.68MN/A-2.367Positive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies INCR Competitors PMVP Competitors VTGN Competitors GNTA Competitors RPTX Competitors IRD Competitors ANEB Competitors IKNA Competitors KLTO Competitors CNTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTXR) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
